Leqembi | pharmaphorum

Wednesday 22 July 2026

Leqembi

News

Donanemab data “strongest yet” in Alzheimer’s

Donanemab data “strongest yet” in Alzheimer’s

Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients t

News

FDA advisors will look at full Leqembi approval in June

FDA advisors will look at full Leqembi approval in June

The FDA has convened a meeting of an advisory committee in June to consider the bid by Eisai and Biogen to convert their accelerated approval of Alzheimer’s disease therap

News

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

Department of Veterans Affairs will cover the drug for veterans with early-stage Alzheimer's.

News

FDA sets July verdict date for Leqembi, after adcomm meeting

FDA sets July verdict date for Leqembi, after adcomm meeting

After priority review, regulator will consider upgrading the drug's status to full approval.

News

drug pricing

Leqembi still too pricey, says ICER in updated review

Side effects create 'uncertainties' as to whether lecanemab's benefits exceed its risks.

News

CMS accused of discrimination over Alzheimer’s drug verdict

CMS accused of discrimination over Alzheimer’s drug verdict

Decision not to revisit coverage decision for amyloid drugs is slammed by patient groups.